Practical clinical application of biochemical markers of bone turnover: Concensus of an expert panel

Journal of Clinical Densitometry

Volumn 2, Issue 3, 1999, Pages 323-342

  Miller, Paul D ^a   Baran, Daniel T ^b   Bilezikian, John P ^c   Greenspan, Susan L ^d   Lindsay, Robert ^e,f   Riggs, B Lawrence ^g   Watts, Nelson B ^h  

^a University of Colorado Health Sciences Center   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c Columbia University ^*  (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f HELEN HAYES HOSPITAL   (United States)

^g MAYO CLINIC   (United States)

^h EMORY CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

AGED; BONE REMODELING; FEMALE; HUMAN; MIDDLE AGED; POSTMENOPAUSE OSTEOPOROSIS; REVIEW;

AGED; BIOLOGICAL MARKERS; BONE REMODELING; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 0033197068     PISSN: 10946950     EISSN: None     Source Type: Journal    
DOI: 10.1385/JCD:2:3:323     Document Type: Review

References (181)

1. WHO Technical Report. 1994 Assessment of fracture risks and its application to screening of postmenopausul osteoporosis. WHO Tech Rep Ser 843:1-129.
2. Baran DT, Faulkner KG, Genant HK, Miller PD, Pacifici R. 1997 Diagnosis and management of osteoporosis: guidelines for the utilization of bone densitometry. Calcif Tissue Int 61:433-440.
3. Miller PD, Bonnick SL, Johnston CC Jr, et al. 1998 The challenges of peripheral bone density testing: which patients need additional central density skeletal measurements? J Clin Densitom 1:211-217.
4. Miller PD, Bonnick SL, Rosen CJ. 1996 Consensus of an international panel on the clinical utility of bone mass measurements in the detection of low bone mass in the adult population. Calcif Tissue Int 58:207-214.
5. Eriksen EF. 1986 Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and metabolic bone disease. Endocr Rev 7:379-408.
6. The Development Committee for the National Osteoporosis Foundation. 1998 Osteoporosis: review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis. Osteoporos Int 8(Suppl. 4):S1-S88.
7. Rosen CJ, Chesnut CH III, Mallinak NJS. 1997 The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement of calcium supplementation. J Clin Endocrinol Metab 82:1904-1910.
8. Data on file. Rahway, NJ: Merck Research Laboratories.
9. Silverman SL, Chesnut C, Andriano K, et al. 1998 Salmon calcitonin nasal spray (NS-CT) reduces risk of vertebral fracture(s) (VF) in established osteoporosis and has continuous efficacy with prolonged treatment: accrued 5 year worldwide data of the PROOF study. Bone 23(Suppl.):S174.
10. Ensrud K, Black D, Recker R, et al. 1998 The effect of 2 and 3 years of raloxifcne on vertebral and non-vertebral fractures in postmenopausal women with osteoporosis. Bone 23(Suppl.):S174.
11. He Y-F, Ross PD, Davis JW, Epstein RS, Vogel JM, Wasnich RD. 1994 When should bone density measurements be repeated? Calcif Tissue Int 55:243-248.
12. Cummings SR, Black DM, Vogt TM, for the FIT Research Group. 1996 Changes in BMD substantially underestimate the anti-fracture effects of alendronate and other antiresorptive drugs. J Bone Miner Res 11:S102.
13. Rosen CJ. 1998 Pre-emptive bone strikes in prevention of osteporosis. Lancet 351:927-928 (editorial).
14. Riis BJ, Hansen MA, Jensen AM, Overgaard K, Christiansen C. 1996 Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study. Bone 19:9-12.
15. van Daele PLA, Seibel MJ, Burger H, et al. 1996 Casecontrol analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study. BMJ 312:482-483.
16. Garnero P, Hausherr E, Chapuy M-C, et al. 1996 Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11:1531-1538.
17. Riggs BL, Melton LJ III, O'Fallon WM. 1996 Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone 18:197S-201S.
18. van Daele PLA, Seibel MJ, Burger H, et al. 1996 Evidence for uncoupling of bone formation and bone resorption in women with hip fractures: a prospective study. Osteoporos Int 6(Suppl. 1):S199.
19. Melton LJ III, Khosla S, Atkinson EJ, O'Fallon WM, Riggs BL. 1997 Relationship of bone turnover to bone density and fractures. J Bone Miner Res 12:1083-1091.
20. Ross PD, Wasnich RD, Knowlton WK. 1997 Skeletal alkaline phosphatase (Tandem®-R Ostase®) measurements predict vertebral fractures: a prospective study. J Bone Miner Res 12(Suppl. 1):S150.
21. Garnero P, Dargent-Molina P, Hans D, et al. 1998 Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS Prospective Study. Osteoporos Int 8:563-569.
22. Calvo MS, Eyre DR, Gundberg CM. 1996 Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 17:333-368.
23. Rosen CJ, Tenenhouse A. 1998 Biochemical markers of bone turnover: a look at laboratory tests that reflect bone status. Postgrad Med 104:101-114.
24. Bikle DD. 1997 Biochemical markers in the assessment of bone disease. Am J Med 103:427-436.
25. Ureña P, Ferreira A, Kung VT, et al. 1995 Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hcmodialysis patients. J Bone Miner Res 10:932-939.
26. Christgau S, Rosenquist C, Alexandersen P, et al. 1998 Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem 44:2290-2300.
27. Gertz BJ, Clemens JD, Holland SD, Yuan W, Greenspan S. 1998 Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int 63:102-106.
28. Prestwood KM, Thompson DL, Kenny AM, Seibel MJ, Pilbeam CC, Raisz LG. 1999 Low dose estrogen and calcium have an additive effect on bone resorption in older women. J Clin Endocrinol Metab 84:179-183.
29. Ravn P, Clemmesen B, Christiansen C, for the Alendronate Osteoporosis Prevention Study Group. 1999 Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Bone 24:237-244.
30. Robinson, R. 1932 The significance of phosphoric esters in metabolism. New York: New York University Press.
31. Riggs BL, Jowsey J, Kelly PJ, Jones JD, Maher FT. 1969 Effect of sex hormones on bone in primary osteoporosis. J Clin Invest 48:1065-1072.
32. Lauffenburger T, Olah AJ, Dumbacher MA, Guncaga J, Lentner C, Haas HG. 1977 Bone remodelling and calcium metabolism: a correlated histomorphometric, calcium kinetic and biochemical study in patients with osteoporosis and Paget's disease. Metabolism 26:589-606.
33. Gallagher JC, Aaron J, Horsman A, Marshall DH, Wilkinson R, Nordin BE. 1973 The crush fracture syndrome in postmenopausal women. J Clin Endocrinol Metab 2:293-315.
34. Lindsay R, Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clarke AC. 1976 Long-term prevention of postmenopausal osteoporosis by oestrogen: evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet 1(7968):1038-1041.
35. Uebelhart D, Schlemmer A, Johansen J, Gineyts E, Christiansen C, Delmas PD. 1991 Effect of menopause and hormone therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab 72:367-373.
36. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. 1996 Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11:337-349.
37. Hesley RP, Shepard KA, Jenkins DK, Riggs BL. 1998 Monitoring estrogen replacement therapy and identifying rapid bone losers with an immunoassay for deoxypyridinoline. Osteoporos Int 8:159-164.
38. Garnero P, Delmas PD. 1993 Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 77:1046-1053.
39. Ebeling PR, Atley LM, Guthrie JR, et al. 1996 Bone turnover markers and bone density across the menopausal transition. J Clin Endocrinol Metab 81:3366-3371.
40. Prior JC, Vigna YM, Wark JD, et al. 1997 Premenopausal ovariectomy-related bone loss: a randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate. J Bone Miner Res 12:1851-1863.
41. Schlemmer A, Hassager C, Delmas PD, Christiansen C. 1994 Urinary excretion of pyridinium cross-links in healthy women: the long-term effects of menopause and oestrogen/progesterone therapy. Clin Endocrinol (Oxf) 40:777-782.
42. Schneider DL, Barrett-Connor EL. 1997 Urinary N-Telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density. Arch Intern Med 157:1241-1245.
43. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700.
44. Hansen MA, Overgaard K, Christiansen C. 1995 Spontaneous postmenopausal bone loss in different skeletal areas: followed up for 15 years. J Bone Miner Res 10:205-210.
45. Ross PD, He Y-F, Davis JW, Epstein RS, Wasnich RD. 1994 Normal ranges for bone loss rates. Bone Miner 26:169-180.
46. Ensrud KE, Palermo L, Black DM, et al. 1995 Hip and calcaneal bone loss increase with advancing age: longitudinal results from the Study of Osteoporotic Fractures. J Bone Miner Res 10:1778-1787.
47. Jones G, Nguyen T, Sambrook P, Kelly PJ, Eisman JA. 1994 Progressive loss of bone in the femoral neck in elderly people: longitudinal findings from the Dubbo Osteoporosis Epidemiology Study. BMJ 309:691-695.
48. Peel NFA, Smith AG, Hannon RA, Eastell R. 1996 Rate of bone loss from lumbar spine in women with distal forearm fracture. BMJ 312:1457.
49. Reginster JY, Deroisy R, Collette J, Albert A, Zegels B. 1997 Prediction of bone loss rate in healthy postmenopausal women. Calcif Tissue Int 60:261-264.
50. Greenspan SL, Maitland LA, Myers ER, Krasnow MB, Kido TH. 1994 Femoral bone loss progresses with age: a longitudinal study in women over age 65. J Bone Miner Res 9:1959-1965.
51. Sklarin PM, Cummings SR, Nevitt MC, et al. 1996 Bone loss is an independent predictor of hip fracture in elderly women with low bone mass. 10th International Congress on Endocrinology, San Francisco, June 12-15.
52. Johansen JS, Riis BJ, Delmas PD, Christiansen C. 1988 Plasma BGP: an indicator of spontaneous bone loss and of the effect of oestrogen treatment in postmenopausal women. Eur J Clin Invest 18:191-195.
53. Mole PA, Walkinshaw MH, Robins SP, Paterson CR. 1992 Can urinary pyridinium crosslinks and urinary oestrogens predict bone mass and rate of bone loss after the menopause? Eur J Clin Invest 22:767-771.
54. Dresner-Pollak R, Parker RA, Poku M, Thompson J, Seibel MJ, Greenspan SL. 1996 Biochemical markers of bone turnover reflect femoral bone loss in elderly women. Calcif Tissue Int 59:328-333.
55. Slemenda C, Longcope C, Peacock M, Hui S, Johnston CC Jr. 1996 Sex steroids, bone mass, and bone loss: a prospective study of pre-, peri- and postmenopausal women. J Clin Invest 97:14-21.
56. Cosman F, Nieves J, Wilkinson C, Schnering D, Shen V, Lindsay R. 1996 Bone density change and biochemical indices of skeletal turnover. Calcif Tissue Int 58:236-243.
57. Cummings SR, Black D, Ensrud K, et al. 1996 Urine markers of bone resorption predict hip bone loss and fractures in older women: the Study of Osteoporotic Fractures. J Bone Miner Res 11(Suppl. 1):S128.
58. Ross PD, Knowlton W. 1998 Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res 13:297-302.
59. Ross PD, Armour KW, Mizrahi IA, Kress BC. 1997 Skeletal alkaline phosphatase (Tandem®-R Ostase®) measurements predict rapid bone loss during 13 years follow up. J Bone Miner Res 12(Suppl. 1):S138.
60. Ohishi T, Takahashi M, Kushida K, et al. 1998 Urinary collagen crosslinks reflect further bone loss of femoral neck in Osteoporotic patients undergoing vitamin D therapy. Endocr Res 24:259-267.
61. Faulkner KG, McClung MR. 1995 Quality control of DXA instruments in multicenter trials. Osteoporos Int 5:218-227.
62. Marshall D, Johnell O, Wedel H. 1996 Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254-1259.
63. Miller PD, McClung M. 1996 Prediction of fracture risk I: bone density. Am J Med Sci 312:257-259.
64. Vergnaud P, Garnero P, Meunier PJ, Bréart G, Kamihagi K, Delmas PD. 1997 Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS study. J Clin Endocrinol Metab 82:719-724.
65. Siddiqi A, Burrin JM, Noonan K, et al. 1997 A longitudinal study of markers of bone turnover in Graves' disease and their value in predicting bone mineral density. J Clin Endocrinol Metab 82:753-759.
66. Seibel MJ, Gartenberg F, Silverberg SJ, Ratcliffe A, Robins SP, Bilezikian JP. 1992 Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism. J Clin Endocrinol Metab 74:481-486.
67. Alvarez L, Guañabens N, Peris P, et al. 1995 Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. J Bone Miner Res 10:458-165.
68. Pecherstorfer M, Seibel MJ, Woitge HW, et al. 1997 Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen. Blood 90:3743-3750.
69. Vinholes J, Coleman R, Eastell R. 1996 Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev 22:289-331.
70. Sorenson S. 1988 Wheat-germ lectin agglutination method for measuring bone and liver isoenzymes of alkaline phosphatase assessed in postmenopausal osteoporosis. Clin Chem 34:1636-1640.
71. Hassager C, Colwell A, Assiri AMA, Eastell R, Russell RGG, Christiansen C. 1992 Effect of menopause and hormone replacement therapy on urinary excretion of pyridinium crosslinks: a longitudinal and cross-sectional study. Clin Endocrinol 37:45-50.
72. Lufkin EG, Wahner HW, O'Fallon WM, et al. 1992 Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 117:1-9.
73. Field CS, Dry SJ, Wahner HW, Herrmann RR, Judd HL, Riggs BL. 1993 Preventive effects of transdermal 17β-estradiol on osteoporotic changes after surgical menopause: a two-year placebo-controlled trial. Am J Obstet Gynecol 168:114-121.
74. Hashimoto K, Nozaki M, Yokoyamu M, Sano M, Nakano H. 1994 Urinary excretion of pyridinium crosslinks of collagen in oophorectomized women as markers for bone resorption. Maturitas 18:135-142.
75. Rosenquist C, Bonde M, Fledelius C. Qvist P. 1994 A simple enzyme-linked immunosorbent assay of human osteocalcin. Clin Chem 40:1258-1264.
76. Gambacciani M, Spinetti A, Cappagli B, et al. 1994 Hormone replacement therapy in perimenopausal women with a low dose oral contraceptive preparation: effects on bone mineral density and metabolism. Maturitas 19:125-131.
77. Yasuda M, Kurabayashi T, Yamamoto Y, Fujimaki T, Oda K, Tanaka K. 1994 Effect of hormone replacement therapy on bone and lipid metabolism in women oophorectomized for the treatment of gynecologic malignancies. Int J Gynecol Obstet 47:151-156.
78. Cantatore FP, Cincinelli E, Galantino P, et al. 1995 Evaluation of bone turnover and bone mass during taper-ing estrogen therapy: a preliminary report. Arthritis Rheum 38:292-294.
79. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. 1995 Applications of an enzyme immunoassay for a new marker of bone rcsorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 80:864-868.
80. McKane WR, Khosla S, Burritt MF, et al. 1995 Mechanism of renal calcium conservation with estrogen replacement therapy in women in early postmenopause. J Clin Endocrinol Metab 80:3458-3464.
81. Alexandersen P, Hassager C, Riis BJ. 1995 The effect of menopause and hormone replacement therapy on bone alkaline phosphatase. Scand J Clin Lab Invest 55:571-576.
82. Rosenquist C, Qvist P, Bjarnason N, Christiansen C. 1995 Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem 41:1439-1445.
83. Chen JT, Hosoda K, Hasumi K, Ogata E, Shiraki M. 1996 Serum N-terminal osteocalcin is a good indicator for estimating responders to hormone replacement therapy in postmenopausal women. J Bone Miner Res 11:1784-1792.
84. Tobias JH, Laversuch CJ, Chambers TJ, Gallagher AC. 1996 Aminohexane bisphosphonate suppresses bone turnover in postmenopausal women more rapidly than oestrogen-gestagen therapy. Br J Rheumatol 35:636-641.
85. Aloia JF, Vaswani A, Yeh JK, Russo L. 1996 Differential effects of dietary calcium augmentation and hormone replacement therapy on bone turnover and scrum levels of calcitrophic hormones. Osteoporos Int 6:55-62.
86. Overgaard K, Alexandersen P, Riis BJ, Christiansen C. 1996 Evaluation of a new commercial IRMA for bone-specific alkaline phosphatase during treatment with hormone replacement therapy and calcitonin. Clin Chem 42:973, 974.
87. Pedrazzoni M, Alfano FS, Girasole G, et al. 1996 Clinical observations with a new specific assay for bone alkaline phosphatase: a cross-sectional study in osteoporotic and pagetic subjects and longitudinal evaluation of the response to ovariectomy, estrogens, and bisphosphonates. Calcif Tissue Int 59:334-338.
88. Cicinelli E, Cantatore FP, Galantino P, et al. 1996 Effects of continuous percutaneous estradiol administration on skeletal turnover in postmenopausal women: a 1-year prospective controlled study. Eur J Obstet Gynecol Reprod Bio 69:109-113.
89. Chesnut CH III, Bell NH, Clark G, et al. 1997 Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 102:29-37.
90. Gonnelli S, Cepollaro C, Pondrelli C, Martini S, Monaco R, Gennari C. 1997 The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis. J Bone Miner Res 12:624-631.
91. Naessen T, Berglund L, Ulmsten U. 1997 Bone loss in elderly women prevented by ultralow doses of parenteral 17β-estradiol. Am J Obstet Gynecol 177:115-119.
92. Heikkinen A, Parviainen M, Niskanen L, et al. 1997 Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study. J Clin Endocrinol Metab 82:2476-2482.
93. Devogelaer JP, Lecart C, Dupret P, De Nayer P, De Deuxchaisnes CN. 1998 Long-term effects of percutaneous estradiol on bone loss and bone metabolism in postmenopausal hysterectomized women. Maturitas 28:243-249.
94. Taga M, Uemura T, Minaguchi H. 1998 The effect of hormone replacement therapy in postmenopausal women on urinary C-telopeptide and N-telopeptide of Type I collagen, new markers of bone resorption. J Endocrinol Invest 21:154-159.
95. Hannon R, Blumsohn A, Naylor K, Eastell R. 1998 Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 13:1124-1133.
96. Harris ST, Gertz BJ, Genant HK, et al. 1993 The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 76:1399-1406.
97. Gertz BJ, Shao P, Hanson DA, et al. 1994 Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res 9:135-142.
98. Rossini M, Gatti D, Zamberlan N, Braga V, Dorizzi R, Adami S. 1994 Long-term effects of a treatment course with oral alendronale of postmenopausal osteoporosis. J Bone Miner Res 9:1833-1837.
99. Adami S, Passeri M, Ortolani S, et al. 1995 Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 17:383-390.
100. Chesnut CH III, McClung MR, Ensrud KE, et al. 1995 Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 99:144-152.
101. Devogelaer JP, Broll H, Correa-Rotter R, et al. 1996 Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 18:141-150.
102. Tucci JR, Tonino RP, Emkey RD, et al. 1996 Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 101:488-501.
103. Bone H, Downs RW Jr, Tucci J, et al. 1997 Doseresponse relationships for alendronate treatment in osteoporotic elderly women. J Clin Endocrinol Metab 82:265-274.
104. Pouilles JM, Tremollieres F, Roux C, et al. 1997 Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy. Osteoporos Int 7:213-218.
105. Meunier PJ, Confavreux E, Tupinon I, Hardouin C, Delmas PD, Balena R. 1997 Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up). J Clin Endocrinol Metab 82:2784-2791.
106. Bettica P, Bevilacqua M, Vago T, Masino M, Cucinotta E, Norbiato G. 1997 Short-term variations in bone remodeling biochemical markers: cyclical etidronate and alendronate effects compared. J Clin Endocrinol Metab 82:3034-3039.
107. Stock JL, Bell NH, Chesnut CH III, et al. 1997 Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 103:291-297.
108. Herd RJM, Balena R, Blake CM, Ryan PJ, Fogelman I. 1997 The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study. Am J Med 103:92-99.
109. McClung M, Clemmesen B, Daifotis A, et al. 1998 Alendronate prevents postmenopausal bone loss in women without osteoporosis: a double-blind, randomised, controlled trial. Ann Intern Med 128:253-261.
110. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB. 1998 Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 13:1431-1438.
111. Machado ABC, Hannon R, Eastell R. 1999 Monitoring alendronate therapy in osteoporosis. J Bone Miner Res 14:602-608.
112. Civitelli R, Gonnelli S, Zacchei F, et al. 1988 Bone turnover in postmenopausal osteoporosis: effect of calcitonin treatment. J Clin Invest 82:1268-1274.
113. Overgaard K, Riis BJ, Christiansen C, Podenphant J, Johansen JS. 1989 Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol 30:435-442.
114. Mazzuoli GF, Tabolli S, Bigi F, et al. 1990 Effects of salmon calcitonin on the bone loss induced by ovariectomy. Calcif Tissue Int 47:209-214.
115. Fioretti P, Gambacciani M, Taponeco F, Melis GB, Capelli N, Spinetti A. 1992 Effects of continuous and cyclic nasal calcitonin administration in ovariectomized women. Maturitas 15:225-232.
116. Overgaard K. 1994 Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study. Calcif Tissue Int 55:82-86.
117. Thamsborg G, Jensen JEB, Kollerup G, Range EM, Melsen F, Sorensen OH. 1996 Effeet of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis. Bone 18:207-212.
118. Overgaard K, Christiansen C. 1996 A new biochemical marker of bone resorption for follow-up on treatment with nasal salmon calcitonin. Calcif Tissue Int 59:12-16.
119. Ellerington MC, Hillard TC, Whitecroft SIJ, et al. 1996 Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif Tissue Int 59:6-11.
120. Kraenzlin ME, Seibel MJ, Trechsel U, et al. 1996 The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: evidence of maximal effect after 8 weeks of continuous treatment. Calcif Tissue Int 58:216-220.
121. Grigoriou O, Papoulias I, Vitoratos N, et al. 1997 Effects of nasal administration of calcitonin in oophorectomized women: 2-year controlled double-blind study. Maturitas 28:147-151.
122. Ongphiphadhanakul B, Piaseu N, Chailurkit L, Rajatanavin R. 1998 Suppression of bone resorption in early postmenopausal women by intranasal salmon calcitonin in relation to dosage and basal bone turnover. Calcif Tissue Int 62:379-382.
123. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Ames RW, Reid IR. 1995 The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med 99:636-641.
124. Kenny AM, Prestwood KM, Pilbeam CC, Raisz LG. 1995 The short term effects of tamoxifen on bone turnover in older women. J Clin Endocrinol Metab 80:3287-3291.
125. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. 1996 A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 11:835-842.
126. Delmas PD, Bjarnason NH, Mitlak BH, et al. 1997 Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641-1646.
127. Riis BJ, Overgaard K, Christiansen C. 1995 Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy. Osteoporos Int 5:276-280.
128. Garnero P, Delmas PD. 1996 New developments in biochemical markers for osteoporosis. Calcif Tissue Int 59(Suppl. 1):S2-S9.
129. Meunier PJ, Boivin G. 1997 Bone mineral density reflects bone mass but also the degree of mineralization of bone: therapeutic implications. Bone 21:373-377.
130. Frost HM. 1997 Osteoporoses: Their Nature, and Therapeutic Targets (insights from a new paradigm). In: Anabolic Treatments for Osteoporosis. Whitfield JF, Morley P, eds Boca Raton, FL:CRC Press, 1-29.
131. Dempster DW. 1997 Exploiting and bypassing the bone remodeling cycle to optimize the treatment of osteoporosis. J Bone Miner Res 12:1152-1154 (editorial).
132. Overgaard K, Hansen MA, Jensen SB, Christiansen C. 1992 Effect of salcatonin given intranasally on bone mass and fracture rate in established osteoporosis: a dose-response study. BMJ 305:556-561.
133. Singer FR, Melvin KE, Mills BG. 1976 Acute effects of calcitonin on osteoclasts in man. Clin Endocrinol (Oxf) 5(Suppl.):333S-340S.
134. Evans G, Bryant HU, Magee D, Sato M, Turner RT. 1994 The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 134:2283-2288.
135. McClung MR, Faulkner KG, Ravn P, et al. 1996 Inability of baseline biochemical markers to predict bone density changes in early postmenopausal women. J Bone Miner Res 11(Suppl.):S127.
136. Gonnelli S, Cepollaro C, Pondrelli C, Rossi B, Monaco R, Gennari C. 1997 The usefulness of bone turnover in predicting the response to alendronate in postmenopausal osteoporosis. Bone 4(Suppl.):33S.
137. Wimalawansa SJ. 1998 A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 104:219-226.
138. Lindsay R, Cosman F, Cary DJ, et al. 1998 Effect of alendronate added to ongoing hormone replacement therapy on the bone mineral density of women with postmenopausal osteoporosis. Bone 23(Suppl.):S597.
139. Cosman F, Lindsay R, Harris ST, et al. 1998 Alendronate added to ongoing hormone replacement therapy in the treatment of osteoporosis: effect on biochemical markers of bone turnover. Bone 23(Suppl.):S309.
140. Greenspan S, Bankhurst A, Bell N, et al. 1998 Effects of alendronate and estrogen, alone or in combination, on bone mass and turnover in postmenopausal osteoporosis. Bone 23(Suppl.):S174.
141. Watts NB, Becker P. 1999 Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate. Bone 24:65-68.
142. Nielsen HK, Brixen K, Mosekilde L. 1990 Diurnal rhythm in serum activity of wheat-germ lectin-precipitable alkaline phosphatase: temporal relationships with the diurnal rhythm of serum osteocalcin. Scand J Clin Lab Invest 50:851-856.
143. Schlemmer A, Hassager C, Jensen SB, Christiansen C. 1992 Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. J Clin Endocrinol Metab 74:476-480.
144. Eastell R, Calvo MS, Burritt MF, Offord KP, Russell GG, Riggs BL. 1992 Abnormalities in circadian patterns of bone resorption and renal calcium conservation in type I osteoporosis. J Clin Endocrinol Metab 74:487-494.
145. Greenspan SL, Dresner-Pollak R, Parker RA, London D, Ferguson L. 1997 Diurnal variation of bone mineral turnover in elderly men and women. Calcif Tissue Int 60:419-423.
146. Ju H-SJ, Leung S, Brown B, et al. 1997 Comparison of analytical and biological variability of three bone resorption assays. Clin Chem 43:1570-1576.
147. Nielsen HK, Brixen K, Bouillon R, Mosekilde L. 1990 Changes in biochemical markers of osteoblastic activity during the menstrual cycle. J Clin Endocrinol Metab 70:1431-1437.
148. Gorai I, Chaki O, Nakayama M, Minaguchi H. 1995 Urinary biochemical markers for bone resorption during the menstrual cycle. Calcif Tissue Int 57:100-104.
149. Woitge HW, Scheidt-Nave C, Kissling C, et al. 1998 Seasonal variation of biochemical indexes of bone turnover: results of a population-based study. J Clin Endocrinol Metab 83:68-75.
150. Gallagher JC, Kinyamu HK, Fowler SE, Dawson-Hughes B, Dalsky GP, Sherman SS. 1998 Calciotropic hormones and bone markers in the elderly. J Bone Miner Res 13:475-182.
151. Kleerekoper M, Nelson DA, Peterson EL, et al. 1994 Reference data for bone mass, calciotropic hormones, and biochemical markers of bone remodeling in older (55-75) postmenopausal white and black women. J Bone Miner Res 9:1267-1276.
152. Aloia JF, Mikhail M, Pagan CD, Arunachalam A, Yeh JK, Flaster E. 1998 Biochemical and hormonal variables in black and white women matched for age and weight. J Lab Clin Med 132:383-389.
153. Beck Jensen J-E, Sorensen HA, Kollerup G, Jensen LB, Sorensen OH. 1994 Biological variation of biochemical bone markers. Scand J Clin Lab Invest 54(Suppl.)219:36-39.
154. Gerrits MI, Vecht-Hart IM, Oldenhave A, Thijssen JH. 1998 Comparison of urinary bone resorption markers in women of 40-70 years: day-to-day and long-term variation in individual subjects. Maturitas 30:247-255.
155. Fraser CG, Cummings ST, Wilkinson SP, et al. 1989 Biological variability of 26 clinical chemistry analytes in elderly people. Clin Chem 35:783-786.
156. Ricós C, Jiménez CV, Herńandez A, et al. 1994 Biological variation in urine samples used for analyte measurements. Clin Chem 40:472-477.
157. Seibel MJ, Cosman F, Shen V, et al. 1993 Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. J Bone Miner Res 8:881-889.
158. Rosen HN, Moses AC, Garber J, Ross DS, Lee SL, Greenspan SL. 1998 Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates. Calcif Tissue Int 63:363-368.
159. Mallinak N, Pettinger M, Cain D, Flessland K. 1998 Serum NTx levels monitor hormone replacement therapy in early postmenopausal women. Bone 23(Suppl.):S513.
160. Greenspan SL, Morgan JW, Furstoss KJ, et al. 1998 Measuring response to alendronate therapy in elderly women by serum cross-linked N-telopeptides (NTx) immunoassay. Bone 23(Suppl.):S627.
161. Christgau S, Alexandersen P, Schlemmer A, Bonde M, Qvist P, Christiansen C. 1997 Biological variation in the serum concentration of degradation products derived from the C-terminal telopeptide of type I collagen measured by a new version of the CrossLaps™ ELISA. J Bone Miner Res 12(Suppl. 1):S497.
162. Watts NB, Harris ST, Genant HK, et al. 1990 Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73-79.
163. The Writing Group for the PEPI Trial. 1996 Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 276:1389-1396.
164. Liberman UA, Weiss SR, Bröll J, et al. 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443.
165. Colwell A, Russell RGG, Eastell R. 1993 Factors affecting the assay of urinary 3-hydroxypyridinium crosslinks of collagen as markers of bone
166. Blumsohn A, Hannon RA, Eastell R. 1995 Apparent instability of osteocalcin in serum as measured with different commercially available immunoassays. Clin Chem 41:318-319.
167. Noonan K, Kalu ME, Holownia P, Burrin JM. 1997 Effect of different storage temperatures, sample collection procedures and immunoassay methods on osteocalcin measurement. Eur J Clin Chem Clin Biochem 34:841-844.
168. Garnero P, Grimaux M, Seguin P, Delmas PD. 1994 Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res 9(2):255-264.
169. Masters PW, Jones RG, Purves DA, Cooper EH, Cooney JM. 1994 Commercial assays for serum osteocalcin give clinically discordant results. Clin Chem 40:358-363.
170. Robins SP, Duncan A, McLaren AM. 1991 Structural specificity of an ELISA for the collagen crosslink, pyridinoline: implications for the measurement of free pyridinium crosslinks as indices of resorption in metabolic bone diseases. J Bone Miner Res 6(Suppl. 1):S244.
171. Kamel S, Brazier M, Neri V, et al. 1995 Multiple molecular forms of pyridinolines cross-links excreted in human urine evaluated by chromatographic and immunoassay methods. J Bone Miner Res 10:1385-1392.
172. Seyedin SM, Kung VT, Daniloff YN, et al. 1993 Immunoassay for urinary pyridinoline: the new marker of bone resorption. J Bone Miner Res 8:635-641.
173. Black D, Duncan A, Robins SP. 1988 Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reverse-phase high-performance liquid chromatography. Anal Biochem 169:197-203.
174. Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel MJ. 1994 Direct enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 9:1643-1649.
175. Gomez B Jr, Ardakani S, Evans BJ, Merrell LD, Jenkins DK, Kung VT. 1996 Monoclonal antibody assay for free urinary pyridinium cross-links. Clin Chem 42:1168-1175.
176. Robins SP. 1995 Collagen crosslinks in metabolic bone disease. Acta Orthop Scand 66(Suppl. 266):171-175.
177. Gomez B Jr, Ardakani S, Ju J, et al. 1995 Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 41:1560-1566.
178. The National Osteoporosis Foundation. 1998 Physician's guide to prevention and treatment of osteoporosis. Belle Mead, NJ: Excerpta Medica.
179. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. 1994 Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 40:2022-2025.
180. Hanson DA, Weis MAE, Bollen AM, Maslan SL, Singer FR, Eyre DR. 1992 A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 7:1251-1258.
181. Clemens JD, Herrick MV, Singer FR, Eyre DR. 1997 Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin Chem 43:2058-2063.